IR@PKUHSC  > 北京大学深圳医院
学科主题临床医学
A Population-Based Clinical Trial Comparing Endocervical High-Risk HPV Testing Using Hybrid Capture 2 and Cervista From the SHENCCAST II Study
Belinson, Jerome L.1,5; Wu, Ruifang2; Belinson, Suzanne E.1; Qu, Xinfeng3; Yang, Bin4; Du, Hui2; Wu, Ruosong3; Wang, Chun2; Zhang, Lijie2; Zhou, Yanqiu2; Liu, Ying2; Pretorius, Robert G.6
关键词Hybrid Capture 2 Cervista Cervical cancer screening Human papillomavirus HPV
刊名AMERICAN JOURNAL OF CLINICAL PATHOLOGY
2011-05-01
DOI10.1309/AJCPKA6ATAPBZ6JQ
135期:5页:790-795
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pathology
研究领域[WOS]Pathology
关键词[WOS]GRADE CERVICAL LESIONS ; HUMAN-PAPILLOMAVIRUS ; CANCER ; WOMEN ; PERFORMANCE ; CYTOLOGY ; DETECT ; HR
英文摘要

Our objective was to directly compare the accuracy of the high-risk human papillomavirus (HPV) assays, Hybrid Capture 2 (hc2; Qiagen, Gaithersburg, MD) and Cervista (Hologic, Bedford, MA), in diagnosing cervical intraepithelial neoplasia (CIN) 3 or worse (cancer).

A population-based, cross-sectional study (The Shenzhen Cervical Cancer Screening Trial II) was conducted in Guangdong Province in China. Three high-risk HP V assays, self and direct cervical sampling and cytology, were studied. Abnormal results on any of 6 study tests (33%) resulted in referral to colposcopy. At colposcopy, every patient had at least 5 cervical biopsy specimens obtained.

For 8,556 women between the ages of 25 and 59 years (mean, 38.9 years), the rate for CIN 3 or worse was 1.6% (141/8,556). The sensitivity (confidence interval) values for CIN 3 or worse were 97.9% (94.0%-99.6%) and 95.1% (90.0%-98.0%) for hc2 and Cervista, respectively (P > .05). The specificity (confidence interval) values were 87.8% (87.1%-88.5%) and 90.3% (89.6%-90.9%), respectively P < .05).

Differences in accuracy in diagnosing CIN 3 or worse with the hc2 and Cervista tests are minor and result from the decisions made in selecting the cut points.

语种英语
WOS记录号WOS:000289743400019
资助机构Preventive Oncology International, Cleveland Heights, OH ; Hologic, Bedford, MA ; Shenzhen Female Doctors Association, Shenzhen, Peoples Republic of China
引用统计
被引频次:41[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58930
专题北京大学深圳医院
北京大学口腔医学院_口腔正畸科
作者单位1.Prevent Oncol Int, Cleveland Hts, OH USA
2.Peking Univ, Shenzhen Hosp, Shenzhen, Peoples R China
3.Royal Ladies Clin, Shenzhen, Peoples R China
4.Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA
5.Cleveland Clin, Dept Obstet & Gynecol, Cleveland, OH 44106 USA
6.Kaiser Permanente, Dept Obstet & Gynecol, Fontana, CA USA
推荐引用方式
GB/T 7714
Belinson, Jerome L.,Wu, Ruifang,Belinson, Suzanne E.,et al. A Population-Based Clinical Trial Comparing Endocervical High-Risk HPV Testing Using Hybrid Capture 2 and Cervista From the SHENCCAST II Study[J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY,2011,135(5):790-795.
APA Belinson, Jerome L..,Wu, Ruifang.,Belinson, Suzanne E..,Qu, Xinfeng.,Yang, Bin.,...&Pretorius, Robert G..(2011).A Population-Based Clinical Trial Comparing Endocervical High-Risk HPV Testing Using Hybrid Capture 2 and Cervista From the SHENCCAST II Study.AMERICAN JOURNAL OF CLINICAL PATHOLOGY,135(5),790-795.
MLA Belinson, Jerome L.,et al."A Population-Based Clinical Trial Comparing Endocervical High-Risk HPV Testing Using Hybrid Capture 2 and Cervista From the SHENCCAST II Study".AMERICAN JOURNAL OF CLINICAL PATHOLOGY 135.5(2011):790-795.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Belinson, Jerome L.]的文章
[Wu, Ruifang]的文章
[Belinson, Suzanne E.]的文章
百度学术
百度学术中相似的文章
[Belinson, Jerome L.]的文章
[Wu, Ruifang]的文章
[Belinson, Suzanne E.]的文章
必应学术
必应学术中相似的文章
[Belinson, Jerome L.]的文章
[Wu, Ruifang]的文章
[Belinson, Suzanne E.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。